NLS
October 8, 2013
Today, at 12:45 a.m. CET the earliest, the Nobel Prize in Physics 2013 will be announced. Watch the announcement live here:
Updated: December 3, 2025, 09:47 am
Published: October 8, 2013
Top stories
MedTech Business – October 22, 2026
Swedish medtech company Getinge raised its adjusted EBITA margin to 15.1% in the third quarter of 2026, from 13.1% a year earlier, while organic sales grew 2.1%. The company kept its forecast of 3–5% organic sales growth for the full year.
Pharma Business – October 22, 2026
Finnish pharmaceutical company Orion has upgraded its full-year 2026 outlook for both net sales and operating profit, as royalty income has grown faster than expected so far this year.
Acquisition – October 22, 2026
Swedish investment firm EQT has agreed to acquire diagnostics and life science tools company Qiagen through an all-cash public takeover offer, valuing the company at an enterprise value of about EUR 10.8 billion (USD 12.1 billion), including net debt.
In a new job – October 21, 2026
Thomas Eldered, co-founder of Recipharm and founder of the investment company Flerie, has been appointed senior advisor to Sciety. He brings more than 35 years of experience from the pharmaceutical industry as an entrepreneur, executive, and investor.
Related posts
Biotech article - October 1, 2026
Södertälje-based Anocca has dosed the first patient in Sweden with its TCR-T cell therapy, which targets KRAS G12V mutations in pancreatic cancer. Sweden is the third European country where a patient has received the therapy.
Acquisition - August 18, 2026
LEO Pharma is acquiring worldwide rights to dersimelagon from Japan’s Tanabe Pharma in a deal worth up to USD 435 million, strengthening the Danish company’s rare dermatology pipeline.
In a new job - August 4, 2026
EQL has recruited Oskar Karmlid as its new Chief Supply Chain Officer (CSCO).
Business article - June 29, 2026
The newly formed European Life Sciences Coalition (ELSC) has sent an open letter to leading decision-makers and politicians in the EU and Sweden, urging them to take action.
Biotech Business - June 29, 2026
The board of directors of Cantargia has announced the outcome of the rights issue of shares that was announced on 28 May 2026.
Uncategorized - April 29, 2026
The US‑based company has debuted in combined seed and Series A financing to advance a portfolio of mid‑stage neurology and neuropsychiatry drugs in‑licensed from Eisai and Hansoh.
Biotech Business - December 9, 2025
BioArctic’s partner Eisai has announced that Leqembi (lecanemab), has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China.
This site uses cookies
Read more about our privacy policy
The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.
The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.
The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.